FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a method of purifying a compound of formula 1 and/or improving hygroscopicity of a compound of formula 1, involving conversion of a crude compound of formula 1 in amorphous form to crystalline form A of compound of formula 1 with debyeogram of DF with peaks of 2θ ± 0.2°2θ by 12.27, 12.65, 16.07, 19.06 and 26.48°, wherein the crude compound of formula 1 is a compound in which the content of the compound of formula 1 is 97 wt % or less in an anhydrous form.
Formula 1.
EFFECT: technical result is a novel method of purifying amorphous (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran, which in turn can be used in medicine for treating diseases such as cancer, rheumatoid arthritis, macular degeneration.
4 cl, 10 tbl, 24 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE FORM AND METHOD OF CLEANING SAME | 2011 |
|
RU2604734C2 |
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
| CRYSTALLINE FORMS OF LTA4H INHIBITOR | 2019 |
|
RU2808992C2 |
| CRYSTALLINE FORMS OF MAGL INHIBITOR | 2017 |
|
RU2799564C2 |
| CRYSTALLINE OR AMORPHOUS FORM OF FXR AGONISTS BEING STEROID DERIVATIVES, THEIR PRODUCTION METHOD AND THEIR USE | 2018 |
|
RU2800751C2 |
| SALTS AND CRYSTALLINE FORMS | 2014 |
|
RU2654855C2 |
| CRYSTALLINE FORMS OF 9-AMINOMETHYL-SUBSTITUTED TETRACYCLINE COMPOUND AND THEIR PRODUCTION METHOD | 2017 |
|
RU2764723C2 |
| CRYSTALLINE FORMS OF SOLVATED ILAPRAZOLE | 2007 |
|
RU2464270C2 |
| CO-CRYSTALLINE FORMS OF THEOPHYLLINE | 2022 |
|
RU2805752C2 |
| CRYSTALLINE FORM OF INHIBITOR BISULPHATE JAK AND METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2704795C2 |
